Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Pan-PIM Kinase Inhibitor LGB321 Strongly Increases Ibrutinib Effects in CLL, By Blocking Anti-Apoptotic Pathways and Microenvironmental Interactions

Sarah Decker, PhD, Shifa Saleem, Sandra Kissel, Anabel Zwick, Konrad Aumann, Katja Zirlik, MD, Justus Duyster, Prof., Christine Dierks

Blood (2018) 132 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2018-99-114424

Published: 2018

Journal Articles

The Pan-PIM Kinase Inhibitor LGB321 Affects Apoptotic Pathways and Microenvironmental Interactions in CLL

Sarah Decker, PhD, Sandra Kissel, Konrad Aumann, MD, Thorsten Zenz, Katja Zirlik, MD, Rainer Claus, MD, Justus Duyster, MD, Christine Dierks, MD

Blood (2016) 128 (22): 4370.

https://doi.org/10.1182/blood.V128.22.4370.4370

Published: 2016

Journal Articles

SYK Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia

Marco Benkisser-Petersen, Maike Buchner, Arlette Dörffel, Marcus Dühren von Minden, Kerstin Leberecht, Kathrin Kläsener, Rainer Claus, MD, Ariane Ott, Christine Dierks, Hassan Jumaa, Fabio Malavasi, Michael Reth, Hendrik Veelken, Katja Zirlik, MD

Blood (2015) 126 (23): 2910.

https://doi.org/10.1182/blood.V126.23.2910.2910

Published: 2015

Journal Articles

Combined Inhibition of BCR and IGF1R Signaling Leads to Synergistic Apoptosis Induction in Primary CLL Cells in Vitro

Charlotte Schmidt-Salzmann, MD, Niuscha Yaktapour, PhD, Tilman Brummer, PhD, Katja Zirlik, MD, Rainer Claus, MD

Blood (2015) 126 (23): 4168.

https://doi.org/10.1182/blood.V126.23.4168.4168

Published: 2015

Journal Articles

SYK Inhibition Targets CD38−Mediated Survival and Proliferation Signals in Chronic Lymphocytic Leukemia Cells

Maike Buchner, PhD, Natalie Stickel, MS, Arlette Dörffel, BS, Ariane Ott, BS, Marcus Duehren von Minden, MS, Christine Dierks, MD, Hassan Jumaa, PhD, Hendrik J. Veelken, MD, PhD, Katja Zirlik, MD

Blood (2011) 118 (21): 800.

https://doi.org/10.1182/blood.V118.21.800.800

Published: 2011

Journal Articles

Enhanced Antitumoral Activity of Sorafenib or Cetuximab In Comparison to Etoposide In a Disseminated Human AML Model In Vivo

Julia Schüler, Kerstin Klingner, Katja Zirlik, MD, Heinz-Herbert Fiebig, Joachim Böhm

Blood (2010) 116 (21): 2141.

https://doi.org/10.1182/blood.V116.21.2141.2141

Published: 2010

Journal Articles

The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ+λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients

Fortunato Morabito, MD, Rosaria De Filippi, MD, PhD, Luca Laurenti, MD, Katja Zirlik, MD, Anna Grazia Recchia, PhD, Massimo Gentile, MD, Emanuela Morelli, MD, Solluzzo Cavalcanti, MD, Giancarla Iaccarino, D.Sci, Barbara Amoroso, MD, PhD, Antonino Neri, MD, Giovanna Cutrona, PhD, Manlio Ferrarini, MD, Stefano Molica, MD, Giovanni Del Poeta, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2437.

https://doi.org/10.1182/blood.V116.21.2437.2437

Published: 2010

Journal Articles

HLA-Dependent Immune Selection Pressure on the Idiotype Is Predominantly Driven by Somatic Hypermutation In Malignant Lymphoma but Also Modulates Vh Usage In Normal B Cells

Dimitrios Papaioannou, M.D., Anna-Maria Strothmeyer, M.D., Marcus Dühren-von Minden, M.Sc., Marcelo A. Navarrete, M.D., Katja Zirlik, MD, Kristina Heining-Mikesch, M.D., Hendrik Veelken, M.D., Ph.D.

Blood (2010) 116 (21): 3132.

https://doi.org/10.1182/blood.V116.21.3132.3132

Published: 2010

Journal Articles

Antitumor Activity of Small-Molecule SYK Inhibitor R788 and Fludarabinin Mono- and Combined Therapy in a Human B-CLL Xenograft Model.

Julia Schüler, Maike Buchner, Heinz-Herbert Fiebig, Hendrik Veelken, Katja Zirlik, MD

Blood (2009) 114 (22): 2378.

https://doi.org/10.1182/blood.V114.22.2378.2378

Published: 2009

Journal Articles

TRAF-1 Deficient Mice Show Impaired Monocyte Recruitment and Decreased Atherogenesis

Anna Missiou, MD, Natascha Köstlin, MS, Christian Münkel, MA, Dietmar Pfeifer, PhD, Katja Zirlik, MD, Christoph Bode, MD, Peter Libby, MD, Andreas Zirlik, MD

Blood (2008) 112 (11): 696.

https://doi.org/10.1182/blood.V112.11.696.696

Published: 2008

Journal Articles

Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

Maike Buchner, PhD, Simon Fuchs, MS, Gabriele Prinz, BA, Dietmar Pfeifer, PhD, Kilian Bartholomé, PhD, Nina Chevalier, MD, Laurent Vallat, MD, Jens Timmer, PhD, John G Gribben, MD, DSc, Hassan Jumaa, PhD, Hendrik Veelken, MD, Christine Dierks, MD, Katja Zirlik, MD

Blood (2008) 112 (11): 543.

https://doi.org/10.1182/blood.V112.11.543.543

Published: 2008

Journal Articles

Expansion of BCR-ABL Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation.

Christine Dierks, MD, Ronak Beigi, Mario Stegert, PhD, Katja Zirlik, MD, Annette Schmitt-Graeff, Hendrik Veelken, Markus Warmuth, MD

Blood (2007) 110 (11): 3379.

https://doi.org/10.1182/blood.V110.11.3379.3379

Published: 2007

Journal Articles

Kinetics of Immune Responses and Tumor Burden in Patients with Indolent B Cell Lymphomas Receiving Recombinant Idiotype Vaccination as the Sole Treatment.

Cristina Bertinetti, PhD, Frank Schueler, MD, Kristina Heining-Mikesch, MD, Katja Zirlik, MD, Tina Tomann, MD, Brigitte Franke, MD, Gottfried Dolken, MD, Hendrik Veelken, MD

Blood (2006) 108 (11): 2726.

https://doi.org/10.1182/blood.V108.11.2726.2726

Published: 2006

Journal Articles

Hedgehog Pathway: A New Target for B-Cell Lymphomas an Multiple Myeloma.

Christine Dierks, MD, Jovana Grbic, Katja Zirlik, MD, Roland H. Mertelsman, MD, Markus Warmuth, MD

Blood (2006) 108 (11): 389.

https://doi.org/10.1182/blood.V108.11.389.389

Published: 2006

Journal Articles

Stromal Cells Protect B-CLL Cells from Killing by Antigen-Specific Cytotoxic T Cells.

Katja Zirlik, MD, Meike Burger, MD, Philipp Brantner, MS, Gabriele Prinz, BS, Maike Buchner, MS, John G. Gribben, MD DSc, Hendrik Veelken, MD

Blood (2006) 108 (11): 2814.

https://doi.org/10.1182/blood.V108.11.2814.2814

Published: 2006

NARROW

The Pan-PIM Kinase Inhibitor LGB321 Strongly Increases Ibrutinib Effects in CLL, By Blocking Anti-Apoptotic Pathways and Microenvironmental Interactions

The Pan-PIM Kinase Inhibitor LGB321 Affects Apoptotic Pathways and Microenvironmental Interactions in CLL

SYK Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia

Combined Inhibition of BCR and IGF1R Signaling Leads to Synergistic Apoptosis Induction in Primary CLL Cells in Vitro

SYK Inhibition Targets CD38−Mediated Survival and Proliferation Signals in Chronic Lymphocytic Leukemia Cells

Enhanced Antitumoral Activity of Sorafenib or Cetuximab In Comparison to Etoposide In a Disseminated Human AML Model In Vivo

The Total Amount of Kappa Plus Lambda Serum Immunoglobulin Free Light Chains (sFLC κ+λ) Is a Powerful Independent Predictor of Time to First Treatment In Chronic Lymphocytic Leukemia (CLL) and Allows Definition of a Novel Prognostic Scoring System: A Study of 449 Therapy-naïve Patients

HLA-Dependent Immune Selection Pressure on the Idiotype Is Predominantly Driven by Somatic Hypermutation In Malignant Lymphoma but Also Modulates Vh Usage In Normal B Cells

Antitumor Activity of Small-Molecule SYK Inhibitor R788 and Fludarabinin Mono- and Combined Therapy in a Human B-CLL Xenograft Model.

TRAF-1 Deficient Mice Show Impaired Monocyte Recruitment and Decreased Atherogenesis

Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

Expansion of BCR-ABL Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation.

Kinetics of Immune Responses and Tumor Burden in Patients with Indolent B Cell Lymphomas Receiving Recombinant Idiotype Vaccination as the Sole Treatment.

Hedgehog Pathway: A New Target for B-Cell Lymphomas an Multiple Myeloma.

Stromal Cells Protect B-CLL Cells from Killing by Antigen-Specific Cytotoxic T Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only